SGLT2 versus DPP4 inhibitors for type 2 diabetes

被引：15
|
作者：
Scheen, Andre J. [1 ,2 ]
机构：
[1] CHU Sart Tilman, Dept Med, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium
[2] CHU Sart Tilman, Dept Med, Clin Pharmacol Unit, B-4000 Liege, Belgium
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2013年 / 1卷 / 03期
关键词：
CANAGLIFLOZIN;
D O I：
10.1016/S2213-8587(13)70095-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：168 / 170
页数：4
相关论文
共 50 条
  • [41] Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion
    Hattersley, Andrew T.
    Thorens, Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (10): : 974 - 976
  • [42] Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes
    Corral, Pablo
    Nardelli, Natalia
    Elbert, Alicia
    Aranguren, Florencia
    Schreier, Laura
    CURRENT DIABETES REPORTS, 2025, 25 (01)
  • [43] SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Saisho, Yoshifumi
    DISEASES, 2020, 8 (02)
  • [44] Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes
    Muskiet, Marcel H. A.
    van Bommel, Erik J. M.
    van Raalte, Daniel H.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 188 - 189
  • [45] The role of SGLT2 inhibitors in managing type 2 diabetes
    Tat, Velen
    Forest, Christopher P.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2018, 31 (06): : 35 - 40
  • [46] Clinical implication of SGLT2 inhibitors in type 2 diabetes
    Kim, Go Woon
    Chung, Sung Hyun
    ARCHIVES OF PHARMACAL RESEARCH, 2014, 37 (08) : 957 - 966
  • [47] Clinical implication of SGLT2 inhibitors in type 2 diabetes
    Go Woon Kim
    Sung Hyun Chung
    Archives of Pharmacal Research, 2014, 37 : 957 - 966
  • [48] All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries
    Yazdanfard, P.
    Soerensen, K.
    Pedersen-Bjerregaard, U.
    Andersen, M.
    Zareini, B.
    Torp-Pedersen, C.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [49] Precision medicine in type 2 diabetes: harnessing individual-level trial data alongside routine care records to identify predictors of response to SGLT2 inhibitors and DPP4 inhibitors
    Dennis, J. M.
    Henley, W.
    Jones, A.
    McGovern, A.
    Pearson, E.
    Hattersley, A.
    Shields, B.
    DIABETOLOGIA, 2019, 62 : S178 - S178
  • [50] SGLT2 inhibitors in Type 1 diabetes: is this the future?
    Herring, R.
    Russell-Jones, D. L.
    DIABETIC MEDICINE, 2018, 35 (12) : 1642 - 1643
12345